You've used all available free searches this month | for more free features.
Clincosm LogoSign in Get a demo

Squamous non-small cell lung cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Efficacy Trial in Suzhou (TAB008, Bevacizumab)

Completed
  • Efficacy
  • Suzhou, Jiangsu, China
    TOT
Jun 16, 2022

NSCLC, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Tumor of Lung Trial in United States (sapanisertib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Davis, California
  • +13 more
Nov 7, 2022

Non-squamous Non-small-cell Lung Cancer Trial in Beijing (SIBP04, Avastin, Paclitaxel)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 7, 2022

Advanced Squamous Non Small Cell Lung Cancer Trial in Dallas (Afatinib + Prednisone)

Recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • Afatinib + Prednisone
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 28, 2022

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 19, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

First Line Crizotinib for ALK Rearranged Non-squamous Non-small

Recruiting
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

Camrelizumab in Treatment of Advanced Non-squamous

Recruiting
  • Lung Cancer
  • Nantong, Jiangsu, China
    Department of Pharmacy, Affiliated Hospital of Nantong Universit
May 19, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

Non Small Cell Lung Cancer Trial in Quzhou (Cisplatin / Carboplatin,Gemcitabine,Cindilimab)

Recruiting
  • Non Small Cell Lung Cancer
  • Cisplatin / Carboplatin，Gemcitabine，Cindilimab
  • Quzhou, Zhejiang, China
    Quzhou people's Hospital
Apr 2, 2022

Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

Recruiting
  • Lung Cancer
  • AMG 510
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

Metastatic Non Small Cell Lung Cancer Trial in Japan (Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Datopotamab Deruxtecan
  • +4 more
  • Fukuoka, Japan
  • +3 more
Jan 13, 2023

Non-Squamous Non Small Cell Lung Cancer Trial in Changsha (Anlotinib and Docetaxel)

Recruiting
  • Non-Squamous Non Small Cell Lung Cancer
  • Anlotinib and Docetaxel
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma Trial in Augusta (Cabozantinib,

Recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Augusta, Georgia
    Augusta University Georgia Cancer Center
Mar 6, 2022

First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

Recruiting
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

NSCLC Trial in Tianjin (Tislelizumab, Pemetrexed, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 11, 2022

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Metastatic Non-squamous Non Small Cell Lung Cancer Trial in Worldwide (Cosibelimab, Cisplatin, Carboplatin)

Active, not recruiting
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Vitória, Brazil
  • +21 more
Aug 17, 2022

NSCLC Trial in United States (Napabucasin, Paclitaxel)

Terminated
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Beverly Hills, California
  • +4 more
Apr 4, 2022

Cervical/Supraclavicular Metastasis From Non-small-cell Lung

Recruiting
  • Lung Cancer Metastatic
  • Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes
  • Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes
  • Roma, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Jan 23, 2023

Advanced Squamous Non-Small Cell Lung Carcinoma Trial in Beijing, Tianjin, Kunming (TQB2450, Anlotinib HCl capsule, Tislelizumab

Not yet recruiting
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • Beijing, Beijing, China
  • +3 more
Feb 12, 2023